Our study provides proof-of-principle that cancers with specific genetic defects and dysregulated metabolic cell cycle checkpoints ... cells became sensitive to capecitabine and paclitaxel.

population (patients who underwent random assignment), and safety was analyzed in patients who received at least one cycle of chemotherapy. This study was designed to test the superiority of the ...

We evaluated capecitabine (an oral fluoropyrimidine ... if they had a histologically proven adenocarcinoma, squamous-cell carcinoma, or undifferentiated carcinoma of the esophagus ...

Patients were assessed and completed quality-of-life assessments before each cycle of chemotherapy ... one assigned continuous capecitabine had her diagnosis changed from metastatic breast cancer to ...

The most common any-grade side effects included decreased platelet counts (80.6% and 74.2%), decreased neutrophil counts (80.6% and 54.8%), anemia (58.1% and 61.3%) and decreased white blood cell ...